Abstract:Background We have previously isolated a highly mutated VH1-02 antibody termed group C 76-Q13-6F5 (6F5) that targets a conformational epitope on gp41. 6F5 has the capacity to mediate Ab dependent cell cytotoxicity (ADCC). When the VH1-02 group C 76 antibodies variable chain sequence was reverted to germline (76Canc), this still retained ADCC activity. Due to this ability for the 76Canc germline antibody to functionally target this epitope, we sought to identify a protein target for vaccine development. Methods Initially, we interrogated peptide targeting by screening a microarray containing 29,127 linear peptides. Western blot and ELISAs were used to confirm binding and explore human serum targeting. Autoimmune targeting was further interrogated on a yeast-displayed human protein microarray. Results 76Canc specifically recognized a number of acidic peptides. Meme analysis identified a peptide sequence similar to a non-structural protein of Hepacivirus previously implicated in Kawasaki disease (KD). Binding was confirmed to top peptides, including the Hepacivirus-related and KD-related peptide. On serum competitions studies using samples from children with KD compared to controls, targeting of this epitope showed no specific correlation to having KD. Human protein autoantigen screening was also reassuring. Conclusions This study identifies a peptide that can mimic the gp41 epitope targeted by 76C group antibodies (i.e. a mimotope). We show little risk of autoimmune targeting including any inflammation similar to KD, implying non-specific targeting of this peptide during KD. Development of such peptides as the basis for vaccination should proceed cautiously.

What problem does this paper attempt to address?

### The Problem This Paper Attempts to Solve This paper aims to identify a peptide (mimotope) that can mimic a complex gp41 (Human Immunodeficiency Virus Type 1) epitope, which is associated with a non-structural protein previously thought to be related to Kawasaki disease (KD). Specifically, the researchers hope to develop a vaccine by identifying this peptide and evaluating its potential application in vaccine development. ### Background 1. **HIV Vaccine Development**: Successfully developing an HIV vaccine is a significant public health goal. Many broadly neutralizing antibodies (bnAbs) have been discovered and characterized, but highly mutated antibodies do not necessarily predict neutralization efficacy. 2. **76-Q13-6F5 Antibody**: Researchers previously isolated a highly mutated VH1-02 antibody (76-Q13-6F5, referred to as 6F5) that can target a conformational epitope of gp41 and has the ability to mediate antibody-dependent cellular cytotoxicity (ADCC). 3. **76Canc Antibody**: After reverting the variable chain sequence of 6F5 to the germline (76Canc), the antibody still retained ADCC activity. Since the 76Canc germline antibody can functionally target this epitope, researchers hope to identify a protein target that can be used for vaccine development. ### Methods 1. **Peptide Screening**: A microarray screening of a library containing 29,127 linear peptides was conducted to confirm binding and explore human serum targeting. 2. **Yeast Display Human Protein Microarray**: Further exploration of autoimmune targeting. ### Results 1. **76Canc Specifically Recognizes Acidic Peptides**: Meme analysis identified a peptide sequence related to a non-structural protein (HCV) previously thought to be associated with Kawasaki disease. 2. **Binding Confirmation**: ELISA and competition experiments confirmed binding to top peptides, including HCV-related and Kawasaki disease-related peptides. 3. **Clinical Relevance**: Competition experiments using serum from children with Kawasaki disease and control groups showed no specific correlation, indicating that targeting this peptide in Kawasaki disease is non-specific. 4. **Autoantigen Screening**: Results were reassuring, with no significant autoimmune risk identified. ### Conclusion 1. **Identification of Mimotope**: The study identified a peptide (mimotope) that can mimic the gp41 epitope. 2. **Low Autoimmune Risk**: The study suggests that targeting this peptide is unrelated to the inflammation seen in Kawasaki disease, implying non-specific targeting during Kawasaki disease. 3. **Cautious Vaccine Development**: Vaccine development based on these peptides should proceed with caution. ### Keywords HIV, ADCC, Kawasaki disease, peptide mimotope, Gp41 antibody, Hepatitis C

Identification of a mimotope of a complex gp41 Human Immunodeficiency VIrus epitope related to a non-structural protein of Hepacivirus previously implicated in Kawasaki disease

A Novel Polyclonal Antibody Against Human Cytomegalovirus: General Characteristics and Potential Application in Diagnosis

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Development of Two Potential Diagnostic Monoclonal Antibodies Against Human Cytomegalovirus Glycoprotein B

Screening and Identification of an H-2Kb-Restricted CTL Epitope Within the Glycoprotein of Hantaan Virus

Design and immunological properties of topographic immunogenic determinants of a protein antigen (LDH-C4) as vaccines.

Induction of High Levels of Antibodies Recognizing the Neutralizing Epitope Eldkwa and the D- or K-Position-Mutated Epitopes by Candidate Epitope Vaccines Against Hiv-1

Analysis of Plasmablasts From Children With Kawasaki Disease Reveals Evidence of a Convergent Antibody Response to a Specific Protein Epitope

Immunoinformatics studies and design of a novel multi-epitope peptide vaccine against Toxoplasma gondii based on calcium-dependent protein kinases antigens through an in-silico analysis

Bioinformatics analysis of multi-epitope peptide vaccines against Hepatitis C virus: a molecular docking study

The Recombinant Immunogen with High‐Density Epitopes of ELDKWA and ELDEWA Induced Antibodies Recognizing Both Epitopes on HIV‐1 Gp41

Computational insights in design of Crimean–Congo hemorrhagic fever virus conserved immunogenic nucleoprotein peptides containing multiple epitopes

Immunoinformatic Identification of Multiple Epitopes of gp120 Protein of HIV-1 to Enhance the Immune Response against HIV-1 Infection

Reverse vaccinology approach for identification of epitopes from E1 protein as peptide vaccine against HCV: A proof of concept

Monitoring of the Serum Proteome in Kawasaki Disease Patients Before and after Immunoglobulin Therapy

Broadly cross-reactive mimotope of hypervariable region 1 of hepatitis C virus derived from DNA shuffling and screened by phage display library.

In Silico and In Vitro Evaluation of the Molecular Mimicry of the SARS-CoV-2 Spike Protein by Common Short Constituent Sequences (cSCSs) in the Human Proteome: Toward Safer Epitope Design for Vaccine Development

B cell epitope of human cytomegalovirus phosphoprotein 65 (HCMV pp65) induced anti-dsDNA antibody in BALB/c mice

Protective CD8+ T-cell response against Hantaan virus infection induced by immunization with designed linear multi-epitope peptides in HLA-A2.1/Kb transgenic mice

Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine

In Silico Identification of High-Affinity Ligands of the Hiv-1 Gp120 Protein, Potential Peptidomimetics of Neutralizing Antibody N6